The meaning of donor-specific antibodies after heart transplant
- 1 June 2019
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 24 (3) , 252-258
Abstract
Purpose of review: Antibody-mediated rejection (AMR) is a major contributor of impaired long-term survival after heart transplantation (HTx). The presence of circulating donor-specific antihuman leukocyte antigen (HLA) antibodies (DSAs) is considered as a mandatory criterion for AMR after HTx. DSA are known prognostic biomarkers of outcome, for example, recipients with de-novo DSA have a three-fold increased risk of mortality. Recent findings: Although the awareness of the impact and prognosis of DSA on the survival has been increased in the HTx community over the last decade, the management of DSA pre and posttransplant varies among centers and is mainly based on the experience of transplant physicians. Thus, firm consensus strategies for each HTx recipient should be established by a center advisory board of experts in the field of HLA genetics, transplantation immunology, and HTx to evaluate the immunological risk preoperatively and also continuously during the posttransplant course. Consequently, the recent advances of invasive and noninvasive diagnostic tools should be applied, according to the risk, laboratory findings, and clinical events of the recipient. Such individual strategy will result in tailored therapeutic options. Summary: Novel standards for the management of DSA in HTx recipients on the basis of an interdisciplinary approach of experts will improve diagnostics for personalized medicine.Keywords
This publication has 66 references indexed in Scilit:
- Late Antibody-Mediated Rejection After Heart Transplantation Following the Development of De Novo Donor-Specific Human Leukocyte Antigen AntibodyTransplantation, 2012
- Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody-Mediated Rejection and NonadherenceAmerican Journal of Transplantation, 2011
- New-onset graft dysfunction after heart transplantation—incidence and mechanism-related outcomesThe Journal of Heart and Lung Transplantation, 2011
- Pre- and posttransplantation allosensitization in heart allograft recipients: Major impact of de novo alloantibody production on allograft survivalHuman Immunology, 2011
- Donor-specific antibodies to human leukocyte antigens are associated with and precede antibodies to major histocompatibility complex class I–related chain A in antibody-mediated rejection and cardiac allograft vasculopathy after human cardiac transplantationHuman Immunology, 2010
- On solid-phase antibody assaysThe Journal of Heart and Lung Transplantation, 2010
- Cardiovascular Mortality Among Heart Transplant Recipients With Asymptomatic Antibody-Mediated or Stable Mixed Cellular and Antibody-Mediated RejectionThe Journal of Heart and Lung Transplantation, 2009
- Prior Human Leukocyte Antigen-Allosensitization and Left Ventricular Assist Device Type Affect Degree of Post-implantation Human Leukocyte Antigen-AllosensitizationThe Journal of Heart and Lung Transplantation, 2009
- Unappreciated risk factors for transplant patients: HLA antibodies in blood componentsHuman Immunology, 2004
- Flow cytometric evaluation of pregnancy-induced anti-HLA immunization and blood transfusion-induced reactivationTransplantation, 2002